340 related articles for article (PubMed ID: 25894597)
1. Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme.
Elson A; Paulson E; Bovi J; Siker M; Schultz C; Laviolette PS
J Neurooncol; 2015 May; 123(1):179-88. PubMed ID: 25894597
[TBL] [Abstract][Full Text] [Related]
2. Enhancing tumor apparent diffusion coefficient histogram skewness stratifies the postoperative survival in recurrent glioblastoma multiforme patients undergoing salvage surgery.
Zolal A; Juratli TA; Linn J; Podlesek D; Sitoci Ficici KH; Kitzler HH; Schackert G; Sobottka SB; Rieger B; Krex D
J Neurooncol; 2016 May; 127(3):551-7. PubMed ID: 26830088
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of absolute and normalized apparent diffusion coefficient (ADC) values within the post-operative T2/FLAIR volume as adverse prognostic indicators in glioblastoma.
Elson A; Bovi J; Siker M; Schultz C; Paulson E
J Neurooncol; 2015 May; 122(3):549-58. PubMed ID: 25700835
[TBL] [Abstract][Full Text] [Related]
4. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
[TBL] [Abstract][Full Text] [Related]
5. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.
Ellingson BM; Cloughesy TF; Lai A; Mischel PS; Nghiemphu PL; Lalezari S; Schmainda KM; Pope WB
Neuro Oncol; 2011 Oct; 13(10):1151-61. PubMed ID: 21856685
[TBL] [Abstract][Full Text] [Related]
6. Predicting Glioblastoma Recurrence by Early Changes in the Apparent Diffusion Coefficient Value and Signal Intensity on FLAIR Images.
Chang PD; Chow DS; Yang PH; Filippi CG; Lignelli A
AJR Am J Roentgenol; 2017 Jan; 208(1):57-65. PubMed ID: 27726412
[TBL] [Abstract][Full Text] [Related]
7. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.
Pope WB; Kim HJ; Huo J; Alger J; Brown MS; Gjertson D; Sai V; Young JR; Tekchandani L; Cloughesy T; Mischel PS; Lai A; Nghiemphu P; Rahmanuddin S; Goldin J
Radiology; 2009 Jul; 252(1):182-9. PubMed ID: 19561256
[TBL] [Abstract][Full Text] [Related]
8. Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.
Zhang M; Gulotta B; Thomas A; Kaley T; Karimi S; Gavrilovic I; Woo KM; Zhang Z; Arevalo-Perez J; Holodny AI; Rosenblum M; Young RJ
Neuro Oncol; 2016 May; 18(5):735-43. PubMed ID: 26538618
[TBL] [Abstract][Full Text] [Related]
9. Normalized Apparent Diffusion Coefficient in the Prognostication of Patients with Glioblastoma Multiforme.
Shankar JJ; Bata A; Ritchie K; Hebb A; Walling S
Can J Neurol Sci; 2016 Jan; 43(1):127-33. PubMed ID: 26786643
[TBL] [Abstract][Full Text] [Related]
10. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.
Suchorska B; Weller M; Tabatabai G; Senft C; Hau P; Sabel MC; Herrlinger U; Ketter R; Schlegel U; Marosi C; Reifenberger G; Wick W; Tonn JC; Wirsching HG
Neuro Oncol; 2016 Apr; 18(4):549-56. PubMed ID: 26823503
[TBL] [Abstract][Full Text] [Related]
11. Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma.
McDonald MW; Shu HK; Curran WJ; Crocker IR
Int J Radiat Oncol Biol Phys; 2011 Jan; 79(1):130-6. PubMed ID: 20399036
[TBL] [Abstract][Full Text] [Related]
12. Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma.
Krishnan AP; Karunamuni R; Leyden KM; Seibert TM; Delfanti RL; Kuperman JM; Bartsch H; Elbe P; Srikant A; Dale AM; Kesari S; Piccioni DE; Hattangadi-Gluth JA; Farid N; McDonald CR; White NS
AJNR Am J Neuroradiol; 2017 May; 38(5):882-889. PubMed ID: 28279985
[TBL] [Abstract][Full Text] [Related]
13. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.
Rahman R; Hamdan A; Zweifler R; Jiang H; Norden AD; Reardon DA; Mukundan S; Wen PY; Huang RY
J Neurooncol; 2014 Aug; 119(1):149-58. PubMed ID: 24805151
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of combined visualization of MR diffusion and perfusion maps in glioblastoma.
Deike K; Wiestler B; Graf M; Reimer C; Floca RO; Bäumer P; Kickingereder P; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
J Neurooncol; 2016 Feb; 126(3):463-72. PubMed ID: 26518541
[TBL] [Abstract][Full Text] [Related]
15. Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients.
Rulseh AM; Vymazal J
J Neurooncol; 2020 Jan; 146(1):157-162. PubMed ID: 31797235
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.
Ellingson BM; Sahebjam S; Kim HJ; Pope WB; Harris RJ; Woodworth DC; Lai A; Nghiemphu PL; Mason WP; Cloughesy TF
AJNR Am J Neuroradiol; 2014 Apr; 35(4):673-9. PubMed ID: 24136647
[TBL] [Abstract][Full Text] [Related]
17. Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator.
Kolakshyapati M; Adhikari RB; Karlowee V; Takayasu T; Nosaka R; Amatya VJ; Takeshima Y; Akiyama Y; Sugiyama K; Kurisu K; Yamasaki F
J Neurosurg; 2018 Mar; 128(3):667-678. PubMed ID: 28362236
[TBL] [Abstract][Full Text] [Related]
18. Hypercellularity Components of Glioblastoma Identified by High b-Value Diffusion-Weighted Imaging.
Pramanik PP; Parmar HA; Mammoser AG; Junck LR; Kim MM; Tsien CI; Lawrence TS; Cao Y
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):811-9. PubMed ID: 26104935
[TBL] [Abstract][Full Text] [Related]
19. Lymphomas and glioblastomas: differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3T.
Doskaliyev A; Yamasaki F; Ohtaki M; Kajiwara Y; Takeshima Y; Watanabe Y; Takayasu T; Amatya VJ; Akiyama Y; Sugiyama K; Kurisu K
Eur J Radiol; 2012 Feb; 81(2):339-44. PubMed ID: 21129872
[TBL] [Abstract][Full Text] [Related]
20. Cancer Imaging Phenomics via CaPTk: Multi-Institutional Prediction of Progression-Free Survival and Pattern of Recurrence in Glioblastoma.
Fathi Kazerooni A; Akbari H; Shukla G; Badve C; Rudie JD; Sako C; Rathore S; Bakas S; Pati S; Singh A; Bergman M; Ha SM; Kontos D; Nasrallah M; Bagley SJ; Lustig RA; O'Rourke DM; Sloan AE; Barnholtz-Sloan JS; Mohan S; Bilello M; Davatzikos C
JCO Clin Cancer Inform; 2020 Mar; 4():234-244. PubMed ID: 32191542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
